Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 4,070

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

AASLD guidelines for the treatment of hepatocellular carcinoma

Open access
Heimbach, Julie K., Kulik, Laura M., Finn, Richard S., Sirlin, Claude B., Abecassis, Michael M., Roberts, Lewis R., Zhu, Andrew X., Murad, M. Hassan, Marrero, Jorge A. · 2018 · Hepatology

Abstract

Potential conflict of interest: Laura M. Kulik is on the advisory board for Gilead, Bayer, Eisai, Salix, and Bristol‐Myers Squibb. Richard Finn consults for Pfizer, Bayer, Novartis, Merck, and Bristol‐Myers Squibb. Claude B. Sirlin consults for and has received grants from Virtualscopics. Lewis R. Roberts consults for Wako, Medscape, and Axis; advises Tavec and Bayer; is on the speakers' bureau for Onlive; and has received grants from Ariad, BTG, and Gilead. Andrew Zhu consults for Bristol‐Myers Squibb, Eisai, Merck, Novartis, Sanofi, and Bayer. The funding for the development of this Practice Guideline was provided by the American Association for the Study of Liver Diseases. Guiding Principles and Objectives GUIDING PRINCIPLES This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the surveillance, diagnosis, and treatment of hepatocellular carcinoma (HCC) occurring in the setting of adults with cirrhosis. Unlike previous AASLD practice guidelines, the current guideline was developed in compliance with the Institute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.1 Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline. An enhanced understanding of the guideline can be obtained by reading the applicable portions of the systematic reviews. In addition, more detailed information may be found in the associated guidance document related to clinically important aspects of HCC that lacked sufficient evidence to warrant a systematic review. The guideline focuses on a broad spectrum of clinical practice, including surveillance of patients with cirrhosis for HCC, establishing the diagnosis of HCC, and various therapeutic options for the treatment of HCC. To address other issues on HCC such as epidemiology, staging, and additional aspects of diagnosis and treatment, the authors have created a new guidance document that will be published soon and is based upon the previous HCC AASLD guidelines by Bruix and Sherman.2 KEY QUESTIONS The guideline developers from the AASLD identified key questions that health care providers are faced with frequently in the evaluation and management of patients with HCC. These questions were: Should adults with cirrhosis undergo surveillance for HCC? If so, which surveillance test is best? Should adults with cirrhosis and suspected HCC undergo diagnostic evaluation with multiphasic computed tomography (CT) or multiphasic magnetic resonance imaging (MRI)? Should adults with cirrhosis and an indeterminate hepatic nodule undergo a biopsy, repeated imaging, or alternative imaging for the diagnostic evaluation? Should adults with Child‐Pugh class A cirrhosis and early‐stage HCC (T1 or T2) be treated with resection or local‐regional (LRT) therapy? Should adults with cirrhosis and HCC that has been resected or ablated successfully undergo adjuvant therapy? Should adults with cirrhosis awaiting liver transplantation and HCC (T1) be treated or undergo observation? Should adults with cirrhosis and HCC (Organ Procurement and Transplantation Network [OPTN] T2) awaiting liver transplantation undergo transplantation alone or transplantation with bridging therapy while waiting? Should adults with cirrhosis awaiting liver transplantation and HCC beyond Milan criteria (T3) undergo transplantation after being down‐staged to within Milan criteria? Should adults with cirrhosis and HCC (T2 or T3, no vascular involvement) who are not candidates for resection or transplantation be treated with transarterial chemoembolization, transarterial radioembolization, or external radiation? Should adults with Child‐Pugh class A/B cirrhosis and advanced HCC with macrovascular invasion and/or metastatic disease be treated with systemic or locoregional therapies or no therapy? TARGET AUDIENCE This guideline is intended primarily for health care providers who care for patients with cirrhosis. Additionally, the guideline may inform policy decisions regarding patients with HCC. Background BURDEN OF DISEASE According to the World Health Organization, HCC is the fifth most common tumor worldwide and the second most common cause of cancer‐related death (http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp). Male‐to‐female predominance is greater than 2:1 with liver cancer, and approximately 83% of the estimated 782,000 new HCC cases in 2012 occurred in less developed regions of the world, with East and South Asia plus sub‐Saharan Africa being the regions of highest incidence, Southern Europe and North America being the regions of intermediate incidence, and Northern Europe and South Central Asia being the regions of lowest incidence.3 The incidence of HCC has been rising rapidly in the United States over the last 20 years.4 According to estimates from the Surveillance Epidemiology End Results

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.29086

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Research works printed but not linked: 20

  1. 2015, Screening fundamentals, J Natl Cancer Inst Monogr, 1997, 15
  2. 1980, Basic issues in population screening for cancer, J Natl Cancer Inst, 64, 1263
  3. 2009, Small nodules (1–2ccm) in liver cirrhosis: characterization with contrast‐enhanced ultrasound, Eur J Radiol, 72, 418, 10.1016/j.ejrad.2008.08.011 · doi:10.1016/j.ejrad.2008.08.011
  4. 2010, The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria, Am J Gastroenterol, 105, 599, 10.1038/ajg.2009.654 · doi:10.1038/ajg.2009.654
  5. 2008, Contrast‐enhanced ultrasound assessment of arterial vascularization of small nodules arising in the cirrhotic liver, Dig Liver Dis, 40, 206, 10.1016/j.dld.2007.10.006 · doi:10.1016/j.dld.2007.10.006
  6. 2015, Contrast‐enhanced ultrasound for the differentiation of small atypical hepatocellular carcinomas from dysplastic nodules in cirrhosis, Dig Liver Dis, 47, 775, 10.1016/j.dld.2015.05.001 · doi:10.1016/j.dld.2015.05.001
  7. 2005, Importance of small (≤20‐mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver, Radiology, 237, 938, 10.1148/radiol.2373041364 · doi:10.1148/radiol.2373041364
  8. 2005, Outcome of small (10‐20 mm) arterial phase‐enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease, Am J Gastroenterol, 100, 1523, 10.1111/j.1572-0241.2005.41814.x · doi:10.1111/j.1572-0241.2005.41814.x
  9. 2007, The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liver, Am J Gastroenterol, 102, 1654, 10.1111/j.1572-0241.2007.01338.x · doi:10.1111/j.1572-0241.2007.01338.x
  10. 2008, Small hypervascular hepatocellular carcinoma: limited value of portal and delayed phases on dynamic magnetic resonance imaging, Acta Radiologica, 49, 735, 10.1080/02841850802120045 · doi:10.1080/02841850802120045
  11. 2008, Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three‐dimensional gadobenate dimeglumine‐enhanced hepatic arterial‐phase MRI of the hepatitis B virus‐induced mild cirrhosis, Clin Imaging, 32, 453, 10.1016/j.clinimag.2008.05.002 · doi:10.1016/j.clinimag.2008.05.002
  12. 2010, Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver, J Magn Reson Imaging, 32, 360, 10.1002/jmri.22271 · doi:10.1002/jmri.22271
  13. 2011, Analysis of gadobenate dimeglumine–enhanced MR findings for characterizing small (1–2‐cm) hepatic nodules in patients at high risk for hepatocellular carcinoma, Radiology, 259, 730, 10.1148/radiol.11101549 · doi:10.1148/radiol.11101549
  14. 2008, Validation of the HCC‐MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy, Clin Transplant, 22, 469, 10.1111/j.1399-0012.2008.00811.x · doi:10.1111/j.1399-0012.2008.00811.x
  15. 2015, Transarterial chemoembolization prior to liver transplantation in patients with hepatocellular carcinoma, Ann Transplant, 20, 764, 10.12659/AOT.896778 · doi:10.12659/aot.896778
  16. 2013, Tumor biology and pre‐transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation, Clin Transplant, 27, 311, 10.1111/ctr.12089 · doi:10.1111/ctr.12089
  17. 2004, Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial, Liver Int, 24, 625, 10.1111/j.1478-3231.2004.0963.x · doi:10.1111/j.1478-3231.2004.0963.x
  18. 1993, Treatment of unresectable hepatocellular carcinoma (HCC) by lipiodol‐targeted transcatheter arterial chemoembolization (TACE). A multicenter randomized trial, Hepatology, 18, A58, 10.1016/0270-9139(93)91759-L · doi:10.1016/0270-9139(93)91759-l
  19. 2001, Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC), J Hepatol, 34, 11, 10.1016/S0168-8278(01)80036-2 · doi:10.1016/s0168-8278(01)80036-2
  20. 2015, Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta‐analysis of randomized controlled trials, Int J Clin Exp Med, 8, 10388

Cited by

Metadata

Authors
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A.
Venue
Hepatology
Published
2017-12-19
Volume
67
Issue
1
Pages
358-380
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2582878252
Cited by
4,070
References
78
FWCI
191.27
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.